Unibest

Pharmaceutical intermediates

Tirzepatide Intermediates

3 pharmaceutical intermediates for Tirzepatide. Indication: Obstructive Sleep Apnea Syndrome (OSAS); Obesity; Overweight; Type 2 Diabetes Mellitus.

提交项目All intermediates

About Tirzepatide

Originator
Eli Lilly
Indication
Obstructive Sleep Apnea Syndrome (OSAS); Obesity; Overweight; Type 2 Diabetes Mellitus
Approved Date
07/28/2023
NCE Patent
05/13/2027
DS/DP
01/05/2036

Available intermediates

3 intermediates currently listed for Tirzepatide. Request specifications, documentation or a quotation for any item below.

Tirzepatide intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
AEEA-HCl134979-01-4//
AEEA-AEEA1143516-05-5//
Boc-AEEA-AEEA1069067-08-8//

Other programs under T

Tazemetostat HydrobromideTazobactam SodiumTegoprazanTenapanor HydrochlorideTeneligliptinTetrabenazineTezacaftorTianeptine sodium salt

Building toward Tirzepatide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →